Prime Medicine (PRME) Cash from Investing Activities (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash from Investing Activities data on file, last reported at $43.4 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 190.89% year-over-year to $43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 130.53% YoY) and the FY2025 annual result came in at -$108.8 million, down 258.88% from the prior year.
• Cash from Investing Activities improved to $43.4 million in Q1 2026, from $28.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $50.3 million in Q3 2024 to a low of -$92.1 million in Q3 2025.
• A 5-year average of -$1.5 million and a median of $2.8 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 401.64% — and 2025, when it sank 282.99%.
• Tracing PRME's Cash from Investing Activities over 5 years: stood at -$13.7 million in 2022, then jumped by 401.64% to $41.3 million in 2023, then grew by 16.88% to $48.3 million in 2024, then slumped by 41.29% to $28.3 million in 2025, then jumped by 53.16% to $43.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $43.4 million (Q1 2026), $28.3 million (Q4 2025), and -$92.1 million (Q3 2025), per Business Quant data.